Morgan Stanley Issues Positive Forecast for Zenas BioPharma (NASDAQ:ZBIO) Stock Price

Zenas BioPharma (NASDAQ:ZBIO) had its target price upped by stock analysts at Morgan Stanley from $19.00 to $21.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s target price suggests a potential downside of 9.60% from the company’s previous close.

A number of other equities research analysts have also recently weighed in on ZBIO. Wedbush restated an “outperform” rating and issued a $45.00 price target on shares of Zenas BioPharma in a report on Monday, December 22nd. Guggenheim reaffirmed a “buy” rating on shares of Zenas BioPharma in a report on Monday. HC Wainwright reiterated a “buy” rating and set a $44.00 target price on shares of Zenas BioPharma in a research report on Tuesday, February 10th. Evercore began coverage on Zenas BioPharma in a report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $43.17.

Zenas BioPharma Stock Performance

NASDAQ:ZBIO opened at $23.23 on Tuesday. The firm’s fifty day simple moving average is $22.61 and its 200-day simple moving average is $27.12. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.37. The stock has a market cap of $1.25 billion, a PE ratio of -3.29 and a beta of -1.96. Zenas BioPharma has a fifty-two week low of $6.11 and a fifty-two week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings data on Monday, March 16th. The company reported ($4.54) EPS for the quarter, missing the consensus estimate of ($1.22) by ($3.32).

Insider Activity

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. acquired 57,000 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was acquired at an average cost of $17.96 per share, with a total value of $1,023,720.00. Following the purchase, the chief executive officer directly owned 423,155 shares in the company, valued at approximately $7,599,863.80. This trade represents a 15.57% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Patricia L. Allen acquired 4,160 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The shares were bought at an average price of $26.36 per share, with a total value of $109,657.60. Following the completion of the transaction, the director directly owned 19,860 shares in the company, valued at approximately $523,509.60. The trade was a 26.50% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 202,845 shares of company stock worth $3,747,185 over the last ninety days. 16.50% of the stock is currently owned by insiders.

Institutional Trading of Zenas BioPharma

A number of large investors have recently made changes to their positions in ZBIO. Polar Capital Holdings Plc acquired a new position in Zenas BioPharma in the 4th quarter valued at about $38,402,000. Federated Hermes Inc. grew its holdings in shares of Zenas BioPharma by 45.9% during the fourth quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock worth $98,603,000 after buying an additional 853,740 shares in the last quarter. EcoR1 Capital LLC purchased a new stake in shares of Zenas BioPharma during the fourth quarter worth about $28,667,000. NEA Management Company LLC raised its position in shares of Zenas BioPharma by 28.9% in the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after buying an additional 789,500 shares during the last quarter. Finally, NEXTBio Capital Management LP purchased a new position in shares of Zenas BioPharma during the fourth quarter valued at approximately $11,691,000.

Key Zenas BioPharma News

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Company secured up to $250 million in non-dilutive, multi‑tranche debt financing from Pharmakon to support development and commercialization plans—improves near-term liquidity and reduces immediate dilution risk. Zenas BioPharma Reports Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: Regulatory milestones: Zenas expects to file obexelimab marketing applications for IgG4‑RD with the FDA in Q2 2026 and with the EMA in H2 2026; SunStone SLE topline is due Q4 2026 — these near‑term milestones can materially re‑rate the stock if positive. Zenas BioPharma Reports Fourth-Quarter and Full-Year 2025 Results
• Positive Sentiment: Insider and institutional buying highlighted in recent data (multiple insiders and funds increased stakes), which can signal confidence from management and large holders. Quiver Quant — Inducement Grants (also shows insider activity)
• Neutral Sentiment: Morgan Stanley analyst Judah Frommer maintained a Hold and raised the price target to $21 — the raise is supportive, but the PT remains below some prior analyst targets and near current trading levels, signaling mixed analyst sentiment. TipRanks — Morgan Stanley Rating
• Neutral Sentiment: Company granted inducement stock options (235,700 options at $23.23 and 33,450 RSUs) to new hires to aid recruitment; standard for growth-stage biotech but adds potential future dilution as awards vest. GlobeNewswire — Inducement Grants
• Negative Sentiment: Quarterly GAAP EPS missed heavily: Zenas reported a loss of $4.54 per share vs. consensus roughly -$1.22 — the magnitude of the miss drove investor concern about execution and near‑term profitability. Quarterly Earnings Press Release
• Negative Sentiment: New disclosure of an IPO‑related securities class action expands legal risk and potential financial/operational uncertainty for the company. TipRanks — IPO-Related Securities Class Action

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.